Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks
Sponsor: Promius Pharma, LLC
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Promius Pharma, LLC
More terminations from Promius Pharma, LLC
Other Onychomycosis trials with similar outcome
Listed as NCT01208168, this PHASE3 trial focuses on Onychomycosis and remains terminated or withdrawn. Sponsored by Promius Pharma, LLC, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Promius Pharma, LLC
For direct contact, visit the study record on ClinicalTrials.gov .